![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 11,446 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number : 3265Z Celsis International PLC 18 July 2008 CELSIS INTERNATIONAL PLC ("Celsis", "the Company" or "the Group") Annual Information update 18 July 2008: Celsis International plc, the international life sciences products and laboratory services company, is pleased to provide an annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months preceding this announcement. To avoid a statement of unnecessary length information is referred to in this update rather than included in full. In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred to in this update was up to date at the time the information was published but some information may now be out of date. This annual information update does not constitute an offer of securities addressed to any person and should not be relied on by any person. 1. Announcements made via the Regulatory News Service ("RNS"), a Regulatory Information Service ("RIS"). Date of Publication Regulatory Headline 3 July 2008 Annual Report and Accounts 18 June 2008 Final Results 2 June 2008 Notice of Results 28 May 2008 Holding(s) in Company 24 April 2008 Holding(s) in Company 7 April 2008 Holding(s) in Company 7 April 2008 Holding(s) in Company 27 March 2008 Agreement 27 March 2008 Pre Close Trading Update 7 February 2008 Interim Management Statement 5 February 2008 Holding(s) in Company 16 January 2008 Director/PDMR Shareholding 7 January 2008 Holding(s) in Company 7 January 2008 Holding(s) in Company 3 January 2008 Holding(s) in Company 2 January 2008 Holding(s) in Company 20 December 2007 Holding(s) in Company 31 October 2007 Interim Results 9 October 2007 Notice of Results 27 September 2007 Pre Close Trading Update 24 September 2007 Holding(s) in Company 7 September 2007 Holding(s) in Company 29 August 2007 Director/PDMR Shareholding 14 August 2007 Interim Management Statement 31 July 2007 Director/PDMR Shareholding 26 July 2007 AGM Result 26 July 2007 AGM Statement 18 July 2007 Annual Information Update Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange. 2. Documents filed at Companies House The documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of these documents can be obtained from Companies House. Date Document type Description 26 September 2007 AA Report and Accounts 11 September 2007 363 Annual Return 21 August 2007 288b Director Resigned 24 July 2007 287 Registered office change 3. Documents sent to Shareholders The documents listed below have been despatched by the Company to holders of its securities on or around the following dates. Date Description 30 June 2008 2008 Annual Report and Accounts 30 June 2008 Notice of Annual General Meeting 14 May 2008 Deemed Consent Letter 5 December 2007 2007 Interim Report 4. Documents submitted to the UK Listing Authority Copies of the following documents have been submitted to the UK Listing Authority for inspection at their Document Viewing Facility on or around the following dates and can be obtained from the Company Secretary, Celsis International plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP. Date Description 30 June 2008 2008 Annual Report and Accounts 30 June 2008 Notice of Annual General Meeting 5 December 2007 2007 Interim Report Enquiries: Celsis International plc Tel: +44 (0) 1223 598 428 Christian Madrolle, Company Secretary Jenny Woolway, Corporate Communications Financial Dynamics Tel: +44 (0) 20 7831 3113 David Yates Jonathan Birt Notes to editors Celsis International plc Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L). Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange END AIUZDLFFVDBBBBX
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions